The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | A study of pembrolizumab maintenance as an alternative to autoSCT in R/R Hodgkin lymphoma
Alison Moskowitz, MD, Memorial Sloan Kettering Cancer Center, New York City, NY, discusses a study of pembrolizumab maintenance as a treatment strategy for patients with relapsed/refractory (R/R) Hodgkin lymphoma, moving away from the standard of care of autologous stem cell transplantation (autoSCT). Dr Moskowitz reports that pembrolizumab maintenance following pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as a second-line treatment was effective in some patients, meaning it could be a viable alternative to transplant. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
